Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics: Implications for Precision Medicine - Brief Report

Matthew R. Deshotels, Trevor D. Hadley, Mendel Roth, Ali M. Agha, Vishnu Priya Pulipati, Anne K. Nugent, Salim S. Virani, Vijay Nambi, Patrick M. Moriarty, Michael H. Davidson, Christie M. Ballantyne

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Background: Severe hypertriglyceridemia is often caused by variants in genes of triglyceride metabolism. These variants include rare, heterozygous pathogenic variants (PVs), or multiple common, small-effect single nucleotide polymorphisms that can be quantified using a polygenic risk score (PRS). The role of genetic testing to examine PVs and PRS in predicting risk for pancreatitis and severity of hypertriglyceridemia is unknown. Methods: We examined the relationship of PVs and PRSs associated with hypertriglyceridemia with the highest recorded plasma triglyceride level and risk for acute pancreatitis in 363 patients from 3 academic lipid clinics who underwent genetic testing (GBinsight's Dyslipidemia Comprehensive Panel). Categories of hypertriglyceridemia included: normal triglyceride (<200 mg/dL), moderate (200-499 mg/dL), severe (500-999 mg/dL), or very severe (≥1000 mg/dL). Results: PVs and high PRSs were identified in 37 (10%) and 59 (16%) individuals, respectively. Patients with both had increased risk for very severe hypertriglyceridemia compared with those with neither genetic risk factor. Risk for acute pancreatitis was also increased in individuals with both genetic risk factors (odds ratio, 5.1 [P=0.02] after controlling for age, race, sex, body mass index, and highest triglyceride level), but not in individuals with PV or high PRS alone. Conclusions: The presence of both PV and high PRS significantly increased risk for very severe hypertriglyceridemia and acute pancreatitis, whereas PV or PRS alone only modestly increased risk. Genetic testing may help identify patients with hypertriglyceridemia who have the greatest risk for developing pancreatitis and may derive the greatest benefit from novel triglyceride-lowering therapies.

Original languageEnglish
Pages (from-to)1461-1467
Number of pages7
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Issue number12
Publication statusPublished - 1 Dec 2022
Externally publishedYes


  • genetic testing
  • hypertriglyceridemia
  • pancreatitis
  • polymorphism, single nucleotide
  • triglyceride


Dive into the research topics of 'Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics: Implications for Precision Medicine - Brief Report'. Together they form a unique fingerprint.

Cite this